WAYNE, Pa., March 08, 2019 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a physician-led
biopharmaceutical company focused on dermatological and immuno-inflammatory diseases, today announced it will report financial
results for the fourth quarter and full year 2018, Monday, March 18th, before U.S. financial markets close.
Management will conduct a conference call at 8:00 AM ET to discuss Aclaris’ financial results and provide a general
business update. The conference call will be webcast live over the Internet and can be accessed by logging on to the “Investors”
page of the Aclaris Therapeutics website, www.aclaristx.com, prior to the event. A replay of the webcast will be archived on the Aclaris
Therapeutics website for 30 days following the call.
To participate on the live call, please dial (844) 776-7782 (domestic) or (661) 378-9535 (international),
and reference conference ID 9765869 prior to the start of the call.
About Aclaris Therapeutics, Inc.
Aclaris Therapeutics, Inc. is a dermatologist-led biopharmaceutical company focused on identifying, developing, and
commercializing innovative therapies to address significant unmet needs in aesthetic and medical dermatology, and immunology.
Aclaris’ focus on market segments with no FDA-approved medications or where treatment gaps exist has resulted in the first
FDA-approved treatment for raised seborrheic keratoses and several clinical programs to develop medications for the potential
treatment of common warts, alopecia areata, and vitiligo. For additional information, please visit www.aclaristx.com and follow Aclaris on LinkedIn.
Aclaris Contact
Michael Tung, M.D.
Senior Vice President
Corporate Strategy/Investor Relations
484-329-2140
mtung@aclaristx.com
Media Contact
Sheila Kennedy
Vice President, Corporate Communications
484-321-5559
media@aclaristx.com
